News

Full transparency sets a new standard for quality

Published on July 21, 2017

Blueprint Genetics is committed to provide the highest quality genetic testing for our customers. Since quality is something that can be proven, we are proud to transparently share our full set of quality metrics with you. To be able to show the different aspects of quality in genetic testing, we…

Read more

Blueprint welcomes new investors!

Published on July 11, 2017

We are extremely happy to welcome two new investors on board Blueprint Genetics. Our new partners are Creathor, a venture fund based in Germany, and MTIP (MedTech Innovation Partners), a venture fund based in Switzerland. Our existing investors are also participating in the funding round that totals €14m. As a…

Read more

Subscribe to our newsletter

Introducing the updated and improved ophthalmology genetic diagnostic panels

Published on June 22, 2017

Blueprint Genetics has been working towards improving the quality and performance of genetic diagnostic testing for patients with inherited eye disorders. All panels are based on our unique OS-Seq technology that enables high-quality analysis of single nucleotide variants (SNVs), insertions and deletions (indels) and copy number variations (CNVs). Our technological innovations…

Read more

Research Associate

Published on June 19, 2017

Blueprint Genetics is looking for a highly motivated and skilled Research Associate, starting as soon as possible in Helsinki, Finland.   This position involves planning and executing various research and development projects in the laboratory. An ideal candidate has ability to independently design and conduct molecular biology assays and is familiar…

Read more

Panel update for ophthalmology, gastroenterology, and pulmonology

Published on June 1, 2017

We are excited to announce the latest updates to our test menu. We have added some deep intronic and non-coding variants to the tested target regions that have been reported as pathogenic in the literature and are classified as likely pathogenic or pathogenic in ClinVar. These include for example the recurrent…

Read more

Laboratory Technician

Published on May 30, 2017

Blueprint Genetics is looking for a highly motivated and skilled Laboratory Technician for a full-time position, starting as soon as possible in Helsinki, Finland.   Responsibilities: The duties for this position include but are not limited to the following: Performing laboratory testing (NGS and Sanger sequencing) on patient specimens including…

Read more

Medical and Clinical Laboratory Technician or Technologist

Published on April 27, 2017

We are currently looking for a Medical and Clinical Laboratory Technician or Technologist to join our growing operation in San Francisco. This is a full time position.   Responsibilities: The duties for this position include but are not limited to the following: Receiving, evaluating and processing specimens and accompanying requisitions from our North…

Read more

We are proud to sponsor FDNA’s Year of Discovery again in May to accelerate advancements for patients with metabolic conditions

Published on April 27, 2017

FDNA’s Year of Discovery unites clinicians, labs and patients for rare disease advancements. Throughout the month of May, FDNA and Blueprint Genetics will be driving discoveries for metabolic conditions, including storage disorders. As part of the initiative, Blueprint Genetics has pledged a donation of up to $2,500 in May to…

Read more

New panels for genetic testing of a suspected skeletal dysplasia or skeletal disorder

Published on April 25, 2017

New Comprehensive Skeletal Dysplasias and Disorders panel (186 genes) contains the genes from larger Comprehensive Skeletal/Malformation Syndrome Panel that are relevant for a skeletal phenotype and are included in the Nosology and Classification of Genetic Skeletal Disorders 2015 revision. It offers high differential diagnosis power and limits the tested genes…

Read more

New panels for diagnosing hereditary cancer 

Published on April 25, 2017

We are now providing a more targeted panel for high risk breast cancer diagnostics. The Hereditary Breast Cancer High Risk Panel analyzes seven genes associated with inherited susceptibility to breast cancer. We have also added a new 27-gene panel to our test menu for diagnosing inherited susceptibility to breast and gynecological cancer.

Read more

Board Certified Genetic Counselor

Published on April 5, 2017

We are currently looking for a Board Certified Genetic Counselor to join our Clinical Genetics Support Team. This position is based out of our San Francisco office and will be PT initially but could lead to Full Time.   Responsibilities: The duties for this position include but are not limited…

Read more

We’re hiring a ABMG certified Geneticist to join our Clinical Operation Team

Published on April 3, 2017

We seek a highly motivated individual who can utilize their superior clinical and technical skills in providing state-of-the-art clinical test reports and genetic diagnostic service. We are looking for highly motivated individuals who demonstrate effort and initiative; team players who are willing to accept personal accountability for successful job performance…

Read more

Blueprint receives the BioFinland Award 2017

Published on March 29, 2017

We are very proud and thankful to receive the BioFinland Award 2017, today on March 29th. This is a great recognition to the whole team that constantly works to bring genetic testing of inherited disorders into mainstream healthcare, cost efficiently without ever compromising quality. The awards is presented by the Finnish Bioindustries…

Read more

Billing Support Representative – Blueprint Genetics Inc, San Francisco, CA

Published on March 28, 2017

  We are looking for a Billing Support Representative for our growing US operations. The ideal candidate will have experience billing Genetic Testing services into the payer marketplace and an understanding of the various requirements for reimbursement. This position will also be responsible for patient facing interactions so you must…

Read more

New Face2Gene case report to help phenotype patients

Published on March 27, 2017

FDNA provides a HIPAA-compliant Face2Gene deep learning technology that de-identifies and analyzes cases to identify new phenotypes, facial characteristics and genes that are associated with rare diseases. The new Face2Gene case report enables a clinician to share their patient’s case phenotype with Blueprint Genetics to help improve variant filtering and…

Read more

Foundation Fighting Blindness and Blueprint Genetics Announce Collaboration to Support Genetic Testing and Patient Registry Process for IRD Patients

Published on March 21, 2017

(Columbia, Maryland) – The Foundation Fighting Blindness (FFB), the world’s leading private funder of research for cures for inherited retinal diseases and Blueprint Genetics today announced a collaborative research study to  grow the data in a Foundation-supported patient registry for inherited retinal diseases (IRDs), called “My Retina Tracker”, and,…

Read more

Blueprint Genetics on valittu vuoden 2017 Kasvunrakentajaksi

Published on March 17, 2017

Vuoden 2017 Kasvunrakentaja on Blueprint Genetics. Suomen pääomasijoitusyhdistys – FVCA:n ja PwC:n yhteistyössä järjestämän Kasvunrakentaja 2017 -kilpailun finaalissa etsittiin pääomasijoittajien yli 700 kohdeyhtiön joukosta mielenkiintoisinta ja innostavinta tarinaa. Suomen pääomasijoitusyhdistyksen ja PwC:n Kasvunrakentaja 2017 -kilpailun voittajaksi valittiin Blueprint Genetics, jonka geenitestausteknologia auttaa löytämään harvinaisia perinnöllisiä tauteja.

Read more

We’re hiring Software Engineers to join our Informatics Team

Published on March 17, 2017

Blueprint Genetics is a Next-Generation Sequencing (NGS) company based in Helsinki, Finland. We are a team of more than 50+ professionals running an accredited clinical laboratory providing genetic diagnostics for professional clinical use. Our current diagnostic portfolio includes over 400 tests that cover rare hereditary disorders in 14 medical specialties.

Read more